10-1-2018

A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Julianna Rodin  
*Thomas Jefferson University, Julianna.Rodin@jefferson.edu*

Voichita Bar-Ad  
*Thomas Jefferson University, Voichita.Bar-Ad@jefferson.edu*

David Cognetti  
*Thomas Jefferson University, David.Cognetti@jefferson.edu*

Joseph Curry  
*Thomas Jefferson University, Joseph.Curry@jefferson.edu*

Jennifer Johnson  
*Case Western Reserve University*

*Let us know how access to this document benefits you*

Follow this and additional works at: [https://jdc.jefferson.edu/otofp](https://jdc.jefferson.edu/otofp)

🔗 Part of the [Oncology Commons](https://jdc.jefferson.edu/otofp) and the [Otolaryngology Commons](https://jdc.jefferson.edu/otofp)

**Recommended Citation**

Rodin, Julianna; Bar-Ad, Voichita; Cognetti, David; Curry, Joseph; Johnson, Jennifer; Zender, Chad; Doyle, Laura; Kutler, David; Leiby, Benjamin E.; Keane, William M.; and Luginbuhl, Adam J., "A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery." (2018). *Department of Otolaryngology - Head and Neck Surgery Faculty Papers*. Paper 39.  
[https://jdc.jefferson.edu/otofp/39](https://jdc.jefferson.edu/otofp/39)
Authors
Julianna Rodin, Voichita Bar-Ad, David Cognetti, Joseph Curry, Jennifer Johnson, Chad Zender, Laura Doyle, David Kutler, Benjamin E. Leiby, William M. Keane, and Adam J. Luginbuhl

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/otofp/39
A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery

Julianna Rodin, MD1, Voichita Bar-Ad, MD2, David Cognetti, MD3, Joseph Curry, MD1, Jennifer Johnson, MD, PhD3, Chad Zender, MD1, Laura Doyle, MS2, David Kutler, MD2, Benjamin Leiby, PhD2, William Keane, MD, Adam Luginbuhl, MD1
1Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA, 2Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, 3Department of Otolaryngology, Case Western Reserve University School of Medicine, Cleveland, OH, 4Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 5Department of Otolaryngology, Weill Cornell Medical Center, New York, NY, 6Department of Biostatistics, Thomas Jefferson University, Philadelphia, PA, USA

Abstract

Purpose: To review brachytherapy use in recurrent head and neck carcinoma (RHNC) with focus on its efficacy and complication rates.

Material and methods: A literature search of PubMed, Ovid, Google Scholar, and Scopus was conducted from 1990 to 2017. Publications describing treatment of RHNC with brachytherapy with or without surgery were included. The focus of this review is on oncologic outcomes and the safety of brachytherapy in the recurrent setting.

Results: Thirty studies involving RHNC treatment with brachytherapy were reviewed. Brachytherapy as an adjunct treatment to surgical resection appears to be associated with an improved local regional control and overall survival, when compared with the published rates for re-irradiation utilizing external beam radiotherapy (RT) or brachytherapy alone. Safety data remains variable with different isotopes and dose rates with implantable brachytherapy demonstrating a tolerable side effect profile.

Conclusions: Although surgery remains a mainstay treatment for RHNC, intraoperative interstitial brachytherapy delivery as adjunctive therapy may improve the treatment outcome and may be associated with fewer complication rates as compared to reirradiation using external beam radiotherapy. Further investigations are required to elucidate the role of brachytherapy for RHNC.

J Contemp Brachytherapy 2018; 10, 5: 454–462
DOI: https://doi.org/10.5114/jcb.2018.79399

Key words: cesium, head and neck cancer, recurrent.

Purpose

Head and neck carcinoma (HNC) continue to be a commonly diagnosed cancer with almost 50,000 new cases and almost 10,000 deaths each year [1]. More than 90% of HNC are classified as squamous cell carcinoma, and cases have increased by nearly 5,000 new patients over two years [2,3]. Patients with locally advanced disease generally are treated with an algorithm of surgical resection, radiotherapy (RT), and/or chemoradiotherapy with curative intent. Unfortunately, depending on subsite and stage, almost half of these advanced stage patients fail this approach in the first 5 years [4,5]. The predominant pattern of recurrence is in a locoregional manner [5]. Surgical resection for these patients has become the mainstay of treatment in resectable cases, and re-irradiation as the only locoregional treatment modality for unresectable cases.

Brachytherapy with or without salvage surgery has often been used for this group of cancer patients with RHNC. Compared to external beam radiation therapy (EBRT) delivery systems, including intensity modulated radiation therapy (IMRT) and proton beam therapy, brachytherapy offers focused dose delivery and fewer early toxic effects, while minimizing adjacent non-cancer tissue toxicity, specifically in previously irradiated fields [5]. This protection of adjacent normal tissue can result in preservation of laryngeal and tongue function. Although brachytherapy has been utilized for recurrent head and neck cancer (RHNC) for years, its use has been limited due to availability of technical expertise, variable isotope implantation technical issues, and introduction of IMRT and other alternative EBRT modalities. Brachytherapy can be delivered via permanent implants (using low-dose-rate brachytherapy or LDR or high-dose-rate brachyther-
A systematic review of treating recurrent head and neck cancer involving 131 Cs brachytherapy are also described. The focus on treatment outcomes and complications. Publications in recurrent HNC of various sites, with particular focus included were publications describing brachytherapy use excluding ‘Iodine-125’. The general criteria for the studies to be included were publications describing brachytherapy use in recurrent HNC of various sites, with particular focus on treatment outcomes and complications. Publications involving 131Cs brachytherapy are also described. The search identified a total of 380 papers, with 350 papers being excluded after title and abstract screening. In these excluded papers, brachytherapy in recurrent HNC of various sites was not the chief focus. The remaining 30 studies reported adequate information according to the criteria. Statistical analysis was also performed to compare recurrence rates in studies, which used brachytherapy with surgery versus brachytherapy alone.

**Results**

In the 30 reviewed studies, 95% (1,440 of 1,515 patients) had prior radiation therapy, making radiotherapy treatment options limited. In 23 of these studies, brachytherapy was administered using Iridium-192 (192Ir) in 1,003 patients, Iodine-125 (125I) in 131 patients, and Cesium-131 (131Cs) in 35 patients. Seven studies did not explicitly state which type of isotope was used [8,9,10,11,12,13,14]. Brachytherapy was incorporated into treatment planning with or without salvage surgery in a combined modality approach. Occasionally, brachytherapy was also followed by further radiation therapy or chemotherapy. Reirradiation with brachytherapy was used for local, locoregional, or nodal recurrence or neck disease and not for distant metastatic spread. As with most forms of reirradiation, the toxicity profile of brachytherapy includes neurologic toxicity, dysphagia, carotid artery rupture, skin necrosis, fistulas, and osteoradionecrosis [15,16]. These aspects and other considerations within the studies are described in further detail below.

**Table 1. Overview of studies treating recurrent head and neck squamous cell carcinoma using brachytherapy alone**

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>N</th>
<th>Brachytherapy</th>
<th>Total dose</th>
<th>Additional therapy</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grimard, 2006 [5]</td>
<td>82</td>
<td>Ir 192; LDR</td>
<td>≥ 55 Gy</td>
<td>Surgery (14), EBRT (3), Surgery + EBRT (6)</td>
<td>LC at 2 years: 37% LC at 2 years: 33%</td>
<td>8.5% acute toxicity 22% late toxicity</td>
</tr>
<tr>
<td>Strnad, 2014 [8]</td>
<td>104</td>
<td>PDR</td>
<td>55 Gy or 24 Gy (when +EBRT)</td>
<td>Surgery (51%), EBRT (32%), Chemo (56%)</td>
<td>LC at 5 years: 82% LC at 5 years: 21%</td>
<td>31% late toxicity</td>
</tr>
<tr>
<td>Strnad, 2014 [12]</td>
<td>51</td>
<td>PDR</td>
<td>60 Gy or 27 Gy (when +EBRT)</td>
<td>EBRT (22%), Chemo (69%)</td>
<td>LC at 5 years: 57%</td>
<td>10% acute grade 3 29% late toxicity</td>
</tr>
<tr>
<td>Puthawala, 2001 [17]</td>
<td>220</td>
<td>Ir 192; LDR</td>
<td>Median: 53 Gy</td>
<td>Chemo (88)</td>
<td>LC at 5 years: 51% LC at 5 years: 20%</td>
<td>60% acute toxicity 27% late toxicity (65% of which had RT &gt; 65 Gy)</td>
</tr>
<tr>
<td>Hepel, 2005 [18]</td>
<td>30</td>
<td>Ir 192; HDR</td>
<td>Mean: 34 Gy</td>
<td>Chemo (43%), EBRT (6%)</td>
<td>LC at 2 years: 67% LC at 2 years: 37%</td>
<td>16% late grade 3-4 toxicity</td>
</tr>
<tr>
<td>Jiang, 2011 [19]</td>
<td>29</td>
<td>125I: LDR, US-guided</td>
<td>Median: D90 130 Gy</td>
<td>Not mentioned</td>
<td>LC at 2 years: 35% LC at 2 years: 28%</td>
<td>No carotid rupture or soft tissue/bone necrosis</td>
</tr>
<tr>
<td>Glatzel, 2002 [37]</td>
<td>90</td>
<td>Ir 192; HDR</td>
<td>Median: 17.5 Gy</td>
<td>Not mentioned</td>
<td>Median: OS 6 Mo</td>
<td>7% late grade 3-4</td>
</tr>
<tr>
<td>Zhu, 2013 [32]</td>
<td>19</td>
<td>125I: LDR, US or CT-guided</td>
<td>Median: D90 131 Gy</td>
<td>Not mentioned</td>
<td>LC at 2 years: 27.5% OS at 2 years: 18%</td>
<td>No grade 4 or 5 toxicity</td>
</tr>
<tr>
<td>Meng, 2012 [38]</td>
<td>17</td>
<td>125I: LDR, US or CT-guided</td>
<td>Median: D90 126 Gy</td>
<td>Not mentioned</td>
<td>LC at 2 years: 50% OS at 2 years: 24%</td>
<td>No grade 3 or 4 toxicity</td>
</tr>
<tr>
<td>Wiegand, 2013 [39]</td>
<td>12</td>
<td>Ir 192; HDR</td>
<td>Mean: 20-33 Gy</td>
<td>Not mentioned</td>
<td>Median: OS 8.5 Mo</td>
<td>No serious complications</td>
</tr>
</tbody>
</table>

Brachytherapy for local disease: with and without salvage surgery

Re-irradiation with brachytherapy has been used as an option for resectable and unresectable RHNC cases. While salvage surgery in general is favored, its use may be limited by the extent of disease and the cancer’s intimate anatomic relationship to adjacent structures. Low-dose-rate (LDR), high-dose-rate (HDR), and pulsed-dose-rate (PDR) brachytherapy can be used as monotherapy alone or adjuvantly with salvage surgery. Tables 1 and 2 provide details of all studies using brachytherapy alone and with surgery, respectively. Some of these studies are further described below.

The use of brachytherapy alone was associated with lower local control (LC) and overall survival (OS) rates. In a study by Puthawala et al. [17], 220 patients with RHNC received salvage brachytherapy using LDR interstitial Iridium-192 (192Ir) implants. They achieved 2-, 5-, and 10-year disease-free survival (DFS) rates of 60%, 33%, and 22%, respectively [17]. Hepel et al. [18] found similar results using HDR 192Ir brachytherapy with DFS at 2 years being 45% and OS at 1 and 2 years, 56% and 37%, respectively. Strnad et al. [8] found that their LC rates at 2, 5, and 10 years were 92.5%, 82.4%, and 58.9%, respectively, with a 5-year OS of 21% using PDR brachytherapy. Jiang et al. [19] used LDR 125I ultrasound-guided permanent seeds in patients with RHNC ineligible for salvage surgery, and achieved LC rates at 1, 2, and 3 years of 53.1%, 34.8%, and 17.4%, and OS rates at 1, 2, and 3 years of 54.1%, 27.5%, and 27.5%, respectively.

In the recurrent setting, surgical resection remains the foundation of treatment for resectable disease, when looking at oncologic outcomes. In a study by Grimard et al. [5], brachytherapy was used as monotherapy in 22 of 45 patients and with surgery in 20 of 45 patients [5]. While not statistically significant, salvage surgery with adjuvant brachytherapy led to better locoregional control [5]. Narayana et al. [9] studied patients with recurrent HNC with 18/30 receiving surgery and HDR, 3/30 receiving EBRT and HDR, and 9/30 receiving HDR alone. There was improved local control in patients who received salvage surgery versus those without surgery: 88% vs. 40% [9]. In a study by Rudzianskas et al. [20], 43% of patients

Table 2. Overview of studies treating recurrent head and neck squamous cell carcinoma using surgery with brachytherapy

<table>
<thead>
<tr>
<th>Author, year</th>
<th>N</th>
<th>Brachytherapy</th>
<th>Total dose</th>
<th>Surgical resection</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henderson, 2016 [6]</td>
<td>23</td>
<td>Ir 192; HDR Cs-131; LDR</td>
<td>Mean: 21 Gy Mean: 81 Gy</td>
<td>Yes</td>
<td>Not mentioned</td>
<td>50% toxicity in HDR pts 30% toxicity in LDR pts</td>
</tr>
<tr>
<td>Narayana, 2007 [9]</td>
<td>30</td>
<td>HDR</td>
<td>34 Gy (+ surgery) 20 Gy (+ EBRT) 40 Gy (only BT)</td>
<td>60% Yes 40% No</td>
<td>LC at 2 years: 71% (88% + surgery, 40% – surgery) OS at 2 years: 63%</td>
<td>33% grade 2-3 toxicity</td>
</tr>
<tr>
<td>Martinez-Fernandez, 2017 [10]</td>
<td>63</td>
<td>HDR</td>
<td>Total: 32 or 40 Gy</td>
<td>Yes</td>
<td>LC at 15 years: 41% OS at 15 years: 12%</td>
<td>51% grade ≥ 3 toxicity</td>
</tr>
<tr>
<td>Schiefke, 2008 [11]</td>
<td>13</td>
<td>HDR</td>
<td>Median: 30 Gy</td>
<td>Yes</td>
<td>OS at 2 years: 65% LR failure in 38%</td>
<td>69% acute toxicity 31% late toxicity</td>
</tr>
<tr>
<td>Scala, 2013 [13]</td>
<td>76</td>
<td>HDR</td>
<td>Median rate: 1,200 cGy</td>
<td>Yes</td>
<td>LC at 2 years: 62% OS at 2 years: 42%</td>
<td>No grade 3-4 toxicity</td>
</tr>
<tr>
<td>Rudzianskas, 2012 [20]</td>
<td>30</td>
<td>Ir 192; HDR</td>
<td>Total: 30 Gy</td>
<td>43% Yes 57% No</td>
<td>LC at 2 years: 77% OS at 2 years: 62% Non-surgical group: LC at 2 years: 47% OS at 2 years: 35%</td>
<td>10% acute grade 2-3 10% late grade 2-4</td>
</tr>
<tr>
<td>Park, 1991 [21]</td>
<td>35</td>
<td>I 125; LDR</td>
<td>Mean rate: 8,280 cGy</td>
<td>Yes</td>
<td>OS at 2 years: 38% OS at 5 years: 29%</td>
<td>36% acute and/or late toxicity</td>
</tr>
<tr>
<td>Pellizzon, 2005 [22]</td>
<td>42</td>
<td>Ir 192; HDR</td>
<td>Median: 24 Gy</td>
<td>Yes</td>
<td>Crude LC 57% OS at 5 years: 52.5%</td>
<td>19% acute and/or late toxicity</td>
</tr>
<tr>
<td>Pham, 2015 [23]</td>
<td>18</td>
<td>Cs 131; LDR</td>
<td>Median: 80 Gy</td>
<td>Yes</td>
<td>OS at 18 mos: 45% LR failure in 33%</td>
<td>11% grade 3 toxicity</td>
</tr>
<tr>
<td>Teckie, 2013 [41]</td>
<td>57</td>
<td>Ir 192; HDR</td>
<td>Median: 15 Gy</td>
<td>Yes</td>
<td>OS at 3 years: 32% LR failure in 46%</td>
<td>37% grade 3 No grade 4-5 toxicity</td>
</tr>
<tr>
<td>Perry, 2010 [42]</td>
<td>34</td>
<td>Ir 192; HDR</td>
<td>Median: 15 Gy</td>
<td>Yes</td>
<td>OS at 2 years: 55%</td>
<td>29% grade 3-4 toxicity</td>
</tr>
</tbody>
</table>

Ir 192 – Iridium 192; I 125 – Iodine 125; Cs 131 – Cesium 131; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; EBRT – external beam radiation therapy; BT – brachytherapy; LC – local control; LR – locoregional; OS – overall survival
had surgery and HDR with $^{192}$Ir, while 57% had HDR alone. Patients who received surgery and brachytherapy had improved 2-year local control rates (77%) and OS rates (62%) versus those with brachytherapy alone (47%, 35%, respectively) [20]. These differences in locoregional control underscore the overall benefit of surgical resection in the recurrent setting.

In a study by Park et al. [21], LDR $^{125}$I seeds were implanted in patients with RHNC who all underwent salvage surgery. DFS at 1, 2, and 5 years was 64%, 47%, and 41%, respectively, with a 5-year no evidence of disease (NED) in patients (29%) [21]. Pellizzon et al. [22] studied patients with RHNC treated with surgery and HDR $^{192}$Ir brachytherapy with or without further EBRT and found the OS at 5 and 8 years to be 52.5% and 48.1%. Martinez-Fernandez et al. [10] followed previously irradiated RHNC patients treated with salvage surgery and perioperative HDR brachytherapy for 15 years, finding a 15-year LRC rate of 41.2% and 15-year OS rate of 11.6%. Pham et al. [23] showed that in selected patients, $^{131}$Cs intraoperative seeds with salvage surgery achieved 1-, 2-, and 3-year LC rates of 69%, 62%, and 52%, respectively.

Looking to historic data of re-irradiation using the standard or hyperfractionated IMRT combined with systemic chemotherapy has demonstrated a 2-year survival of 10-25% [24,25]. The previously discussed studies using surgery plus brachytherapy reported a 5-year overall survival of 33-67%, showing encouraging progress over EBRT plus chemotherapy.

We performed a statistical analysis of the studies to evaluate locoregional recurrence in RHNC patients receiving brachytherapy and surgery vs. brachytherapy alone. Logistic regression was used to compare recurrence rates, and generalized estimating equations (GEE) methods were used to account for clustering within the study. In studies where recurrence rates were not explicitly stated, recurrence rates were extrapolated based on the local and locoregional control rates. For the primary analysis, the rate of locoregional recurrence was 38.8% (143/369) in the surgery with brachytherapy group and 49.0% (329/671) in the brachytherapy alone group. The estimated odds ratio was 0.66 (95% CI: 0.38-1.12; p = 0.13).

### Brachytherapy for nodal disease

Many studies also have demonstrated brachytherapy use in RHNC with regional failure in the cervical lymph nodes. Table 3 portrays the details of these studies. In the study by Bartochowska et al. [26], patients with unresectable isolated cervical lymph node recurrence had PDR or HDR with $^{192}$Ir via catheters. Local control rates at 1 and 2 years were 31.7% and 19% [26]. Huang et al. [27] achieved better results in 31 patients with RHNC with neck metastases unmanageable with other techniques, achieving LC rates of 64.5% and 45.1% at 1 and 2 years. In 74 patients with inoperable recurrent lymphadenopathy, Tselis et al. [28] showed OS rates of 42%, 19%, and 6% at 1, 2, and 3 years, respectively.

In the study by Teudt et al. [14], patients with RHNC underwent revision surgery and perioperative HDR for their recurrent neck metastases. These patients were found to have 78% and 67% OS at 2 and 5 years, respectively, with a median survival of 65 months [14]. Nutting et al. [29] also looked at patients with recurrent neck disease undergoing LDR brachytherapy alone, with resection, or with resection and flap surgery. Locoregional control at 2 years in those who had brachytherapy alone was 0%, while those who also had a surgery with or without a flap had improved LRC, 37% or 33%, respectively [29]. For the neck disease statistical analysis, the rate of locoregional recurrence was 30.9% (42/136) in the surgery with brachytherapy group and 49.0% (149/304) in the brachytherapy alone group. The estimated odds ratio was 0.46 (95% CI: 0.25-0.86; p = 0.015).

### Complications

Due to the nature of the radioactive isotopes, brachytherapy is associated with various radiation exposure concerns. However, these radiation effects appear to be improved in terms of functional organ preservation and reduced irradiation to surrounding normal tissues compared to EBRT or IMRT (Quon). Toxicity is commonly monitored using the Radiation Toxicity Oncology Group (RTOG) common toxicity criteria [30]. Radiation safety procedures, including the use of lead shields and gloves, may be appropriate when handling specific radioisotope implants, which is based on a number of factors including isoSteve type, total source activity, and implant location [31]. The recommended limit of radiation exposure to staff personnel based on federal regulation is 50 mSv/ year for “stochastic effects”, e.g., cancer or genetic effects, defined as “ones in which the probability of occurrence increases with increasing absorbed dose, but the severity does not depend on the magnitude of the absorbed dose” [31]. In some cases associated with specific radioisotopes, patients were isolated in order to reduce personnel and family radiation exposure, and were required to stay in the hospital longer.

Toxicity complications related to brachytherapy have been explored in various studies using $^{192}$Ir and $^{125}$I and usually involve necrosis, dysphagia, or fistulas.Tables 1-3 include toxicity rates for studies reviewed. In a review by Kasperts et al. [15], 17% (120/704) of patients developed soft tissue necrosis and 2% (15/704) developed oro-cutaneous fistulas. Another 2% of patients suffered from hemorrhage or carotid blowouts and another 3% developed osteoradionecrosis [15]. In the study by Grimard et al. [5], acute toxicity occurred in 15.6% of patients and late toxicity in 40%, with 4 patients developing grade 2 or 3 radionecrosis and 7 patients experiencing dysphagia. In Zhu et al.’s study [32], only one patient had a grade 1 skin reaction, with no patients suffering from soft tissue necrosis or other complications. Henderson et al. [6] looked at patients who underwent HDR or LDR brachytherapy and neck dissection with or without flap coverage. There were complications in 50% of HDR patients and 29.4% of LDR patients, with only 3 of 22 patients receiving flaps having complications (2 HDR, 1 LDR) [6]. Martinez-Fernandez et al. [10] found RTOG grade 3 or greater toxicities in 50.8% of patients, with 17 cases needing further operations due to fistula (6), wound dehiscence (4), bleeding (3),
or other (4). Notably, many forms of brachytherapy did not use permanent implantable seeds but temporary catheters for the purpose of low-dose or high-dose-rate brachytherapy. Hemorrhage after catheter or tube removal was reported [15].

In contrast, Pham et al. [23] reported similar or lower rates of acute and chronic toxicity with 131Cs as compared to studies using 192Ir and 125I. Only 2 of 18 patients had grade 3 toxicity and none had grade 4-5 toxicity. When present, grade 1-2 complications were primarily dermatitis and hoarseness [23]. The risk to healthcare personnel and close family members has been minimized with isotopes like 131Cs compared to some previous brachytherapy isotopes, which required special precautions [31].

Many prior studies portrayed the effects of 125I and 192Ir brachytherapy on RHNC, but fewer studies have explored the use of permanent 131Cs. 131Cs offers a high-dose-rate, focused delivery, and less radiation exposure to adjacent tissues, personnel, and the patient’s family [23,31]. Compared to 129I, 131Cs has a dose-rate several times higher because of its similar energy but much lower half-life (9.69 days) [33]. This allows for 131Cs to deliver ~90% of its dose in a 33-day period, unlike 32% of the dose delivered by 129I in that time frame [33]. This longer period of time exposes staff and family to potentially increased radiation doses and may require special precautions. Suture strands containing 131Cs seeds can be fixed 0.5-1 cm apart within the tumor bed or come in a pre-imbedded mesh (Figure 1) [31]. With brachytherapy done during salvage surgery, flaps also may help to prevent seed migration and dosimetry alterations. After implantation, seed placement can be monitored radiographically by generating a post-implant plan and toxicity monitored using RTOG common toxicity criteria [30]. In a study by Parasher et al. [31], 28 patients received a median number of twenty 131Cs seeds implanted at 0.5-1 cm distance for lung or HN cancer, with a median seed activity of 2.4 U. Median radiation exposure rate at the skin and at 1 meter was 0.43 mSV and 0.002 mSv, respectively. Minimum measurable radiation dose for OSL badge and TLD ring was 1 mrem and 30 mrem [31]. These minimal dose levels allow for patients to interact with family members and caregivers without special precautions like special lead protective equipment or isolation.

Discussion

Treatment options for RHNC remain limited. Many patients have undergone previous surgeries with or without radiation, chemotherapy, immunotherapies,
and/or combination therapies, which limit retreatment options with radiation in general and EBRT in particular. The most common current treatment for curative intent is salvage surgery but may not be feasible for all cases [34,35,36]. Despite wide margins and G0 resection, locoregional recurrence still thwarts the curative efforts in the recurrent setting. Adding focused radiation directed at the resection margin during salvage surgery, while sparing toxicity to surrounding tissue, is in theory promising.

Brachytherapy has shown to be an effective treatment option with acceptable toxicity profiles for RHNC. When using brachytherapy alone, the reported LR control rates and OS rates at 2 years range from 27.5-92.5% and 18.2-43%, respectively [5,8,12,17,18,19,32,37,38,39]. Some studies have revealed brachytherapy to have enhanced and improved results when combined with salvage surgery [9,20,29,40]. Salvage surgery with brachytherapy as adjuvant therapy has 2-year LR control rates and OS rates ranging from 62-88% and 38-65.3%, respectively [6,9,10,11,13,20,21,22,23,41,42]. Studies by Narayana et al. and Rudzianskas et al. even compared LC and OS rates at 2 years between those who received brachytherapy with and without surgery and found improved rates in those also receiving surgery [9,20]. Although our analysis comparing locoregional recurrence rates of patients receiving surgery with brachytherapy vs. brachytherapy alone was not statistically significant, there was a trend of 38.8% vs. 49.0%. For brachytherapy use in patients with neck disease, LC and OS rates at 2 years had likewise fair responses, with rates ranging from 27.3-67% and 13-78%, respectively [14,24,26,27,28,29,40,43,44]. Many of these studies had recurrent HNC with neck metastases that appeared inoperable or unmanageable with other therapies. Yet, analysis in these neck disease patients did show a statistically significant difference ($p = 0.015$) in locoregional recurrence rates (30.9% vs. 49.0%) between the combined treatment group and brachytherapy alone group, respectively.

In comparison, a review by Goodwin [34] described outcomes using salvage surgery alone, the most common salvage treatment. The weighted average of OS at 3 years was 37% (range: 28-80%) and at 5 years was 36.4% (range: 23-55%) [34]. Goodwin [34] also reported the weighted average of disease-free survival (DFS) rates at 2 years: 36.3% (range: 0-59%). Moreover, a literature review by Strojan et al. [35] examined local control and survival rates using conventional EBRT techniques and newer EBRT techniques like IMRT, with or without surgery, in recurrent HNC. Locoregional control rates and OS rates at 2 years using conventional radiation techniques with salvage surgery ranged from 13-74% (average: 38%) and 21-67% (average: 42.5%), respectively [35]. Newer RT techniques like IMRT have been showing better outcomes. For example, a study by Lee et al. [36] did show that IMRT had improved LR recurrence-free survival at 2 years over conventional RT techniques (52% vs. 20%) but did not significantly improve OS rates. In general, for patients receiving IMRT (with or without salvage

![Fig. 1. A) Post-operative radiographic Cesium-131 seed dosimetry. B) Cesium-131 seed placement intra-operatively](image)
surgery), LR control and OS rates at 2 years ranged from 27-77% and 19.5-58%, respectively [35,45].

Similarly, to some brachytherapy studies, patients receiving reirradiation (either using conventional or newer RT techniques) with salvage surgery had improved outcomes. One phase III randomized trial by Janot et al. [46] divided patients into receiving salvage surgery alone or with adjuvant full-dose reirradiation with chemotherapy. Patients in the radiation arm (using conventional RT) had significantly improved LR control and DFS rates but no significant change in OS rates at 2 years [46]. Likewise, a study by Takiar et al. [47] showed improved disease control and survival outcomes using adjuvant IMRT after surgery (vs. surgery alone) in HNSCC patients with a 5-year OS rate of 57%.

Complications appear less frequent or severe compared to EBRT techniques including IMRT. In some brachytherapy studies, complication rates ranged as high as 50-60% for acute grade 1-2 toxicities including mucositis, dermatitis, hoarseness, infection, or hematoma [12,14,17,26,27]. Late grade 3-4 toxicities included complications like fistula, soft tissue necrosis, ORN, dysphagia, fibrosis, trismus, severe hemorrhage, and wound dehiscence, with rates ranging from 7-51% [9,10,12,17,18,20,21,28,29,37,40,42]. In the study by Takiar et al. [47] using IMRT for re-irradiation, there was a 5-year grade ≥ 3 toxicity rate of 48%, with three patients dying due to radiation toxicity. However, the majority of patients who now are receiving their first round of radiation with IMRT may likely have fewer overall complications, if or when they receive reirradiation. Literature is limited at this time to support this theory but will likely be shown in coming years.

We propose an algorithm to help guide treatment options for patients with RHNC (Figure 2). For example, for patients with resectable locoregional recurrence, consider surgical resection followed by brachytherapy or EBRT with or without chemotherapy or immunotherapy. Using brachytherapy versus external radiation techniques like IMRT may depend on the timing, type of previous RT, and location of recurrence. Despite the safety, ease of use, and promising efficacy advantages of $^{131}$Cs, the use for specific RHNC populations requires further investigation. Unfortunately, the majority of published literature is retrospective, and the patient cohorts and treatment approaches used are very heterogeneous. In theory, combining a radiation boost to salvage surgery may provide dual therapy with less radiotherapy toxicity. $^{131}$Cs with salvage surgery and other combinations with immunotherapy may offer a viable treatment pathway for RHNC for some patients and should be studied in future clinical trials. Our institution has recently been studying $^{131}$Cs brachytherapy in RHNC with preliminary promising results. At this time, HDR and PDR appear to be the current techniques of choice due to optimization of implant dosimetry and geometric sparing with and reduced treatment time.

**Conclusions**

Treatment options for RHNC remain challenging. Although brachytherapy alone can be used to treat RHNC, locoregional control rates and overall survival rates are higher when brachytherapy is used as adjunctive therapy to salvage surgery. These rates remain comparable or improved when brachytherapy is utilized in

---

**Fig. 2.** Proposed algorithm for treating recurrent head and neck squamous cell carcinoma
A systematic review of treating recurrent head and neck cancer.

References


